| n (%) | ||
| Non-CAM | CAM | |
| Autoantibody status | (n = 266) | (n = 16) |
| Myositis-specific antibodies | ||
| Jo-1 | 58 (21.8) | 0 |
| PL-7 | 1 (0.4) | 0 |
| PL-12 | 1 (0.4) | 0 |
| EJ | 1 (0.4) | 0 |
| OJ | 3 (1.1) | 0 |
| KS | 1 (0.4) | 1 (6.2) |
| Mi-2 | 16 (6.0) | 2 (12.5) |
| SRP | 7 (2.6) | 0 |
| 155/140 | 11 (4.1) | 8 (50.0) |
| Myositis-associated antibodies | ||
| U1-RNP | 32 (12.0) | 2 (12.5) |
| U3-RNP | 4 (1.5) | 0 |
| Ku | 5 (1.9) | 0 |
| PM-Scl | 29 (10.9) | 0 |
| None of the above autoantibodies | 106 (39.8) | 5 (31.2) |
CAM, cancer-associated myositis.
Numbers do not add up to totals due to the presence of patients with multiple autoantibodies.
Risk of CAM: anti-155/140 antibody positive versus anti-155/140 antibody negative, p = 0.0009, odds ratio 23.2, 95% confidence interval 6.1–84.5.